meta
|
evidence
oncology
Living systematic review and meta-analysis
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
2
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
5
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
durvalumab based treatment
durvalumab plus etoposide and platin
pembrolizumab based treatment
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs etoposide plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
metastasis (brain) NO
metastasis (brain) YES
metastasis (liver )
PDL1 (CPS < 1)
PDL1 (CPS >1)
smoker (Current)
smoker (Former)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Colitis TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hepatitis TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Myositis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Nephritis TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Pancreatitis TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Severe skin reaction TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Uveitis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dizziness AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Headache AE (grade 3-4)
Hypothyroidism AE (grade 3-4)
Leucopenia AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pneumonia AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
deaths (OS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC
1
certainty unassessable
-18%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open